Hydroxypropyl-β-cyclodextrin (HP-CD) is a hydroxyalkyl derivative of native β-cyclodextrin, cyclic oligosaccharide able to form inclusion complexes with many drugs and biomolecules . Cyclodextrins have a possible neuroprotective effect due to their capability to extract and deplete cholesterol from cell membranes . HP-CD is classified as an excipient (cyclodextrins are in fact widely used to improve solubility of poorly water soluble drugs) and it is not been FDA-approved as therapeutic agent. However HP-CD received the "orphan drug designation" in the United States and Europe because it is employed in individual compassionate use for patients suffering from Niemann-Pick type C. This is a fatal neurological disease characterized by an abnormal storage of cholesterol within the cells and in particular nervous cells causing neurodegeneration . Elevated cholesterol levels produce also the accumulation of beta-amyloid (Aβ) in cellular systems and several animal models of Alzheimer's disease (AD) . AD is a chronic neurodegenerative disease which affects nearly 44 million people worldwide and the global cost of Alzheimer's disease and dementia is estimated to be $605 billion . Cholesterol depletion, disruption or inhibition of Aβ aggregation are possible therapeutic approaches of AD.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||Hydroxypropyl-β-cyclodextrin formulated in nasal chitosan microspheres as candidate therapeutic agent in Alzheimer's disease|
GIUNCHEDI, Paolo (Corresponding)
|Data di pubblicazione:||2018|
|Appare nelle tipologie:||1.1 Articolo in rivista|